Cargando…

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

Detalles Bibliográficos
Autores principales:	Abonour, Rafat, Rifkin, Robert, Ailawadhi, Sikander, Lee, Hans C., Gasparetto, Christina, Wagner, Lynne, Durie, Brian, Hardin, James, Terebelo, Howard, Narang, Mohit, Toomey, Kathleen, Tang, Yuexin, Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang, Jagannath, Sundar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430946/ http://dx.doi.org/10.1097/01.HS9.0000970564.52503.e2

Ejemplares similares

Connect MM Registry as a national reference for United States multiple myeloma patients
por: Ailawadhi, Sikander, et al.
Publicado: (2019)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect(®) MM Registry
por: Lee, Hans C., et al.
Publicado: (2021)

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry
por: Richter, Joshua, et al.
Publicado: (2022)

Effect of initial treatment on health‐related quality of life in patients with newly diagnosed multiple myeloma without immediate stem cell transplant intent: results from the Connect(®) MM Registry
por: Abonour, Rafat, et al.
Publicado: (2020)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2020)

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
por: Abonour, Rafat, et al.
Publicado: (2018)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Recognition of early mortality in multiple myeloma by a prediction matrix
por: Terebelo, Howard, et al.
Publicado: (2017)

Response to: Olry de Labry Lima A et al., Cost-effectiveness of lenalidomide maintenance in patients with multiple myeloma who have undergone autologous transplant hematopoietic progenitor cells
por: Dhanasiri, Sujith
Publicado: (2019)

The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q
por: Lee, Dawn, et al.
Publicado: (2018)

The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
por: Schey, Steve, et al.
Publicado: (2017)

Chart review across EU5 in MM post-ASCT patients
por: Ashcroft, John, et al.
Publicado: (2018)

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
por: Uyl‐de Groot, Carin A., et al.
Publicado: (2020)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

LEP Performance at 91.5 GeV
por: Arduini, Gianluigi, et al.
Publicado: (1998)

MON-915 Acute Abdominal Pain and the Pheochromocytoma
por: Weiner, Yotam, et al.
Publicado: (2020)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

1st International Conference of IFToMM Italy
por: Boschetti, Giovanni, et al.
Publicado: (2017)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM)
por: Ho, Matthew, et al.
Publicado: (2021)

P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
por: Usmani, S., et al.
Publicado: (2022)

Prevalence of oral submucous fibrosis among 50,915 Indian villagers.
por: Pindborg, J. J., et al.
Publicado: (1968)

Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1
por: Mateos, María-Victoria, et al.
Publicado: (2017)

P901: POMALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN LENALIDOMIDE–PRETREATED MULTIPLE MYELOMA: A SUBANALYSIS OF OPTIMISMM BY FRAILTY
por: Oriol, A., et al.
Publicado: (2022)

915 MHz microwave-assisted laparoscopic partial splenectomy: A case series
por: Zhang, Qiyi, et al.
Publicado: (2020)

Microwave Sintering of Alumina at 915 MHz: Modeling, Process Control, and Microstructure Distribution
por: Marinel, Sylvain, et al.
Publicado: (2019)

P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
por: Rifkin, R. M., et al.
Publicado: (2022)

Frequency of genomic incidental findings among 21,915 eMERGE network participants
por: Gordon, Adam S., et al.
Publicado: (2020)

Measurements and Models of 915 MHz LoRa Radio Propagation in an Underground Gold Mine
por: Branch, Philip
Publicado: (2022)

Analysis of Asphericity and Corneal Longitudinal Spherical Aberration of 915 Chinese Myopic Adult Eyes
por: Zhang, Jun, et al.
Publicado: (2023)

Examining the Determinants of COVID-19 Severity: A Cohort Study in Morocco of 915 Patients
por: Mahdi, Zaynab, et al.
Publicado: (2022)

915. Prevalence and Treatment of Genital Herpes in a United States Administrative Claims Database
por: Viscidi, Emma, et al.
Publicado: (2023)

MM-239: A Tertiary Center Experience of Multiple Myeloma Patients with COVID-19: Lessons Learned and the Path Forward
por: Wang, Bo, et al.
Publicado: (2020)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)
por: Kalff, Anna, et al.
Publicado: (2021)

Potential of Sub-GHz Wireless for Future IoT Wearables and Design of Compact 915 MHz Antenna
por: Di Serio, Adolfo, et al.
Publicado: (2017)

TGF-β1 polymorphisms -509 C>T and +915 G>C and risk of pancreatic cancer
por: Behboudi Farahbakhsh, Faegheh, et al.
Publicado: (2017)

915. Global 2018 Surveillance of Eravacycline Against Gram-positive Pathogens, Including Resistant Isolates
por: Morgan, Steven, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qajjqd42l1mreqv5cdn8hfhcre